We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Boehringer Ingelheim posted positive trial results for another Humira biosimilar, just a month after the FDA approved Amgen’s version, Amjevita. Read More